MKI67 and neoplasm: The study included 85 treatment-naive patients with well-differentiated (Ki67 < 2%) locally inoperable or metastatic midgut NETs (functioning and non-functioning) and they were randomly assigned to either octreotide LAR (30 mg monthly intramuscularly) or placebo for 18 months until tumor progression or death.